Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

Core Insights - Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases [3] - The company will participate in a fireside chat at Guggenheim's SMID Cap Biotech Conference on February 5, 2025 [1] - A live webcast of the presentation will be available on the company's website, with replays accessible for 30 days [2] Company Overview - Cabaletta Bio's CABA™ platform includes two strategies aimed at advancing engineered T cell therapies for autoimmune diseases [3] - The lead strategy, CARTA, focuses on the investigational therapy rese-cel, which is a fully human CD19-CAR T cell therapy containing 4-1BB [3] - Rese-cel is currently being evaluated in the RESET™ clinical development program across multiple therapeutic areas, including rheumatology, neurology, and dermatology [3]